Get the Stockscreener App
7.59
0.26%
0.02
After Hours:
7.47
-0.12
-1.58%
Xeris Biopharma Holdings Inc stock is traded at $7.59, with a volume of 1.56M.
It is up +0.26% in the last 24 hours and up +47.67% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$7.57
Open:
$7.6
24h Volume:
1.56M
Relative Volume:
0.66
Market Cap:
$1.23B
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-18.07
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
+3.97%
1M Performance:
+47.67%
6M Performance:
+102.40%
1Y Performance:
+167.25%
1-Day Range:
$7.51
$7.73
1-Week Range:
$7.205
$7.79
52-Week Range:
$2.48
$7.79
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.59 | 1.19B | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Johnson, director, sells Xeris Biopharma (XERS) shares for $786k - Investing.com
Johnson, director, sells Xeris Biopharma (XERS) shares for $786k By Investing.com - Investing.com Nigeria
Independent Director Dawn Halkuff Sold A Bunch Of Shares In Xeris Biopharma Holdings - simplywall.st
Can Xeris Biopharma Holdings Inc. expand its profit margins2025 Market Outlook & Precise Swing Trade Alerts - sundaytimes.kr
Tools to assess Xeris Biopharma Holdings Inc.’s risk profile2025 Earnings Impact & Weekly High Potential Stock Alerts - Newser
Is Xeris Biopharma Holdings Inc. stock a good dividend stockQuarterly Portfolio Report & Stock Portfolio Risk Control - thegnnews.com
Will Xeris Biopharma Holdings Inc. benefit from macro trendsMarket Performance Recap & Capital Efficiency Focused Ideas - Newser
Insider Selling at Xeris Biopharma: A Signal or a Strategy? - AInvest
Xeris Biopharma Director Dawn Halkuff Sells 42,500 Shares at $7.28 Each. - AInvest
Xeris Biopharma (NASDAQ:XERS) Upgraded at HC Wainwright - Defense World
Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k By Investing.com - Investing.com Nigeria
Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k - Investing.com
Xeris Biopharma (NASDAQ:XERS) Raised to “Buy” at HC Wainwright - Defense World
How high can Xeris Biopharma Holdings Inc. stock goDollar Strength & Entry and Exit Point Strategies - Newser
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated by Analysts at HC Wainwright - Defense World
Using Python tools to backtest Xeris Biopharma Holdings Inc. strategiesReal Time Stock Movement and Alerts - Newser
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why - Yahoo Finance
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Xeris Biopharma Earns Buy Rating from HC Wainwright with $10 PT - AInvest
Can trapped investors hope for a rebound in Xeris Biopharma Holdings Inc.Momentum Prediction Based on AI Backtesting - Newser
How liquid is Xeris Biopharma Holdings Inc. stockSpeedy Gain Trade Picks - thegnnews.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Wyckoff Accumulation Phase Possible in Xeris Biopharma Holdings Inc.Potential Breakout Stock List Published This Week - beatles.ru
Bollinger Bands Show Potential Breakout in Xeris Biopharma Holdings Inc.Day Trading Signals With High Precision Reviewed - beatles.ru
How Xeris Biopharma Holdings Inc. stock performs during market volatilityForecast Model for Intraday Buy Signals - Newser
Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript - Insider Monkey
Xeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase Following Better-Than-Expected Earnings - Defense World
Xeris Biopharma (NASDAQ:XERS) Upgraded to “Strong-Buy” at Wall Street Zen - Defense World
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - NewsBreak: Local News & Alerts
XERS (Xeris Biopharma Holdings) Momentum Rank : 3 (As of Aug. 08, 2025) - GuruFocus
XERS Crosses Above Average Analyst Target - Nasdaq
Xeris Biopharma Reports Record Q2 2025 Revenue, Raises Full-Year Guidance - AInvest
Xeris Biopharma: Q2 Earnings Snapshot - Connecticut Post
Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High Following Earnings Beat - Defense World
Xeris Biopharma Reports Strong Q2 2025 Results - TipRanks
Beyond the Balance Sheet: What SWOT Reveals About Xeris Biopharm - GuruFocus
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Transcript : Xeris Biopharma Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Xeris Biopharma Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Little Excitement Around Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Revenues - 富途牛牛
Xeris (XERS) Q2 Revenue Jumps 49% - The Motley Fool
Xeris Biopharma shares rise 24.23% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xeris Biopharma Stock Soars 12.02% on Record Q2 Earnings - AInvest
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - BioSpace
Earnings Flash (XERS) Xeris Biopharma Posts Q2 Net Loss $0.01 a Share, vs. FactSet Est of $0.05 Loss - MarketScreener
Xeris Biopharma beats Q2 revenue expectations, raises FY guidance - MarketScreener
Mackenzie Financial Corp Has $780,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Institutional scanner results for Xeris Biopharma Holdings Inc.Trade Flow Monitor with Volume Tracker - Newser
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HALKUFF DAWN | Director |
Aug 12 '25 |
Sale |
7.28 |
42,500 |
309,226 |
115,000 |
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):